Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sopharma ad - bulgaria - paracetamolum - compr. - 500mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sopharma ad - bulgaria - paracetamolum - compr. - 500mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

pharma-q holdings (pty) ltd - injection - see ingredients - each 1 ml liquid contains epinephrine bitartrate 1,80 mg equivalent to epinephrine 1 mg

Alemanha - alemão - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

pharma gerke arzneimittelvertriebs gmbh (3343338) - procarbazinhydrochlorid - hartkapsel - 50 mg - teil 1 - hartkapsel; procarbazinhydrochlorid (07727) 58,3 milligramm

União Europeia - tcheco - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - gaucherova choroba - ostatní produkty trávicího traktu a metabolismu - miglustat dipharma je indikován k perorální léčbě dospělých pacientů s mírnou až střední gaucherovou chorobou typu 1. miglustat dipharma může být použit pouze k terapii pacientů, pro které není vhodná enzymatická substituční terapie. miglustat dipharma je indikován pro léčbu progredujících neurologických projevů u dospělých a dětských pacientů s niemann-pickova choroba typu c.

União Europeia - tcheco - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin-dihydrochloridu - fenylketonurie - jiné zažívací trakt a produkty metabolismu, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

União Europeia - italiano - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - malattia di gaucher - altri prodotti per il tratto alimentare e il metabolismo - miglustat dipharma è indicato per il trattamento orale di pazienti adulti con lieve o moderata della malattia di gaucher di tipo 1. miglustat dipharma può essere utilizzato solo per il trattamento di pazienti per i quali la terapia di sostituzione enzimatica è inadatto. miglustat dipharma è indicato per il trattamento di progressiva manifestazioni neurologiche in pazienti adulti e pazienti pediatrici con malattia di niemann-pick di tipo c, malattia.

União Europeia - italiano - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dicloridrato - phenylketonurias - altro apparato digerente e metabolismo prodotti, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

União Europeia - dinamarquês - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - gaucher sygdom - andre fordøjelseskanaler og stofskifteprodukter - miglustat dipharma er angivet for den mundtlige behandling af voksne patienter med mild til moderat type 1 gaucher sygdom. miglustat dipharma kan kun anvendes i behandling af patienter, for hvem enzymsubstitutionsbehandlingen er uegnet. miglustat dipharma er indiceret til behandling af progressive neurologiske forstyrrelser hos voksne patienter, og pædiatriske patienter med niemann-picks sygdom type c.

União Europeia - dinamarquês - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dihydrochlorid - phenylketonurias - andre alimentary tract and metabolism produkter, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.